Dimensional Fund Advisors LP Spectrum Pharmaceuticals Inc Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$0.65 - $1.31 $26 - $52	-40 Reduced 0.01%	371,752 $356,000
Q1 2023 May 12, 2023	SELL	$0.38 - $1.07 $25,813 - $72,686	-67,931 Reduced 15.45%	371,792 $278,000
Q3 2022 Nov 10, 2022	SELL	$0.43 - $1.56 $8,669 - $31,452	-20,162 Reduced 4.38%	439,723 $189,000
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.4 $49,042 - $98,084	-70,060 Reduced 13.22%	459,885 $358,000
Q1 2022 May 13, 2022	SELL	$0.63 - $1.59 $246,190 - $621,337	-390,778 Reduced 42.44%	529,945 $683,000
Q4 2021 Feb 09, 2022	SELL	$1.27 - $2.42 $613,667 - $1.17 Million	-483,203 Reduced 34.42%	920,723 $1.17 Million
Q3 2021 Nov 12, 2021	SELL	$2.15 - $3.82 $932,513 - $1.66 Million	-433,727 Reduced 23.6%	1,403,926 $3.06 Million
Q2 2021 Aug 12, 2021	SELL	$2.89 - $4.45 $457,050 - $703,763	-158,149 Reduced 7.92%	1,837,653 $6.89 Million
Q1 2021 May 14, 2021	BUY	$2.9 - $4.09 $1.05 Million - $1.48 Million	361,571 Added 22.12%	1,995,802 $6.53 Million
Q4 2020 Feb 25, 2021	BUY	$3.38 - $5.14 $5.52 Million - $8.4 Million	1,634,231 New	1,634,231 $5.58 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.